GenScript Biotech publishes 2025 annual report

• GenScript Biotech released its 2025 annual report, highlighting strong top-line momentum across core platforms, led by a step-change in licensing activity at ProBio.
• ProBio shifted to profitability on an adjusted basis, supported by sublicense income tied to LaNova’s PD-1/VEGF bispecific program.
• GenScript Life Science Group expanded gene-to-protein workflows, supported by automation and capacity build-out across US, Singapore, and China.
• Bestzyme advanced international expansion while increasing investment in AI-enabled protein engineering to speed industrial enzyme R&D.
• Reported results were weighed by GenScript’s equity-method exposure to Legend, including a large non-cash impairment, despite continued commercial traction for CARVYKTI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260413-12103411), on April 13, 2026, and is solely responsible for the information contained therein.